Martin Maier

Martin is Vice President, Research heading the RNAi Discovery group at Alnylam Pharmaceuticals and co-leading an interdisciplinary research team focused on RNAi platform technology. In these roles, Dr. Maier has contributed to the development of lipid nanoparticles and GalNAc conjugates, two clinically validated platforms for siRNA delivery, and the advancement of multiple therapeutic programs to development, which culminated in the approval of ONPATTRO™, the first-ever RNAi therapeutic and GIVLAARI™, the first GalNAc conjugate. Martin received his Ph.D. in Organic Chemistry in 1997 from the University of Tübingen, Germany with Professor Ernst Bayer. After his postdoctoral research at Isis (now Ionis) Pharmaceuticals, he assumed a permanent position working on novel chemistries and delivery systems for antisense oligonucleotides. Martin has more than 20 years of experience in the field of oligonucleotide therapeutics in both, ASO and RNAi platforms and authored more than 70 peer-reviewed scientific publications, reviews, and book chapters, and is the inventor on more than 30 issued patents.